CLIN CHEM LAB MED:马拉松和超越野跑过程中ST2和galectin-3的变化

2020-03-17 MedSci原创 MedSci原创

既往研究表明,运动有可能会导致心脏损伤。Galectin-3 (Gal-3)和可溶性抑制致瘤性2 (ST2)心力衰竭和心肌纤维化的生物标志物。

既往研究表明,运动有可能会导致心脏损伤。Galectin-3 (Gal-3)和可溶性抑制致瘤性2 (ST2)心力衰竭和心肌纤维化的生物标志物。我们的目的是比较以耐力跑者和休闲跑者为代表的马拉松和超跑事件之前和之后的新兴纤维化心脏生物标志物Gal-3和ST-2的动力学变化。

在跑步(T0)之前,结束(T1)和结束后3小时(T2),从代表健康对照组(10 km)的19名健康非精英马拉松运动员(42 km),27名超跑运动员(67 km)和14名休闲运动员中抽取血液,以分析Gal-3,ST2,hsTnT,NT-proBNP,CKMB和hsCRP。 我们比较了参加三个不同组的不同跑步者组之间从T0到T1(pT0T1)和从T1到T2(pT1T2)的进化百分比和斜率。

血浆心脏生物标志物浓度从基线到运动后立即显著升高,在随后的3-h内大部分时间呈下降趋势。pT0T1和pT1T2中,Gal-3和ST2标记物在跑步类型间有显著性差异(p < 0.05和p < 0.0001)。在恢复期间,Gal-3恢复到基线值,而ST2没有继续增加。

研究结果表明,Gal-3和ST2是心肌纤维化和重构的反映。两者的演变是不同的,特别是在恢复时间之后。 ST2值随时超过截止值。

原始出处:

Caroline Le Goff,Jean-François Kaux,Evolution of the slopes of ST2 and galectin-3 during marathon and ultratrail running compared to a control group

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2068099, encodeId=07f42068099b6, content=<a href='/topic/show?id=3e9816e266d' target=_blank style='color:#2F92EE;'>#ST2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16726, encryptionId=3e9816e266d, topicName=ST2)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Wed Feb 17 03:28:44 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774447, encodeId=02c81e74447ce, content=<a href='/topic/show?id=a0f3e814af' target=_blank style='color:#2F92EE;'>#Galectin-3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7814, encryptionId=a0f3e814af, topicName=Galectin-3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68c038536731, createdName=liuquanmn, createdTime=Thu Aug 13 12:28:44 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428964, encodeId=be41142896478, content=<a href='/topic/show?id=6d4810145692' target=_blank style='color:#2F92EE;'>#马拉松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101456, encryptionId=6d4810145692, topicName=马拉松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=334a4156364, createdName=zxl730, createdTime=Thu Mar 19 08:28:44 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610356, encodeId=28e716103560f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 19 08:28:44 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2068099, encodeId=07f42068099b6, content=<a href='/topic/show?id=3e9816e266d' target=_blank style='color:#2F92EE;'>#ST2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16726, encryptionId=3e9816e266d, topicName=ST2)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Wed Feb 17 03:28:44 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774447, encodeId=02c81e74447ce, content=<a href='/topic/show?id=a0f3e814af' target=_blank style='color:#2F92EE;'>#Galectin-3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7814, encryptionId=a0f3e814af, topicName=Galectin-3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68c038536731, createdName=liuquanmn, createdTime=Thu Aug 13 12:28:44 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428964, encodeId=be41142896478, content=<a href='/topic/show?id=6d4810145692' target=_blank style='color:#2F92EE;'>#马拉松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101456, encryptionId=6d4810145692, topicName=马拉松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=334a4156364, createdName=zxl730, createdTime=Thu Mar 19 08:28:44 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610356, encodeId=28e716103560f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 19 08:28:44 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2068099, encodeId=07f42068099b6, content=<a href='/topic/show?id=3e9816e266d' target=_blank style='color:#2F92EE;'>#ST2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16726, encryptionId=3e9816e266d, topicName=ST2)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Wed Feb 17 03:28:44 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774447, encodeId=02c81e74447ce, content=<a href='/topic/show?id=a0f3e814af' target=_blank style='color:#2F92EE;'>#Galectin-3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7814, encryptionId=a0f3e814af, topicName=Galectin-3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68c038536731, createdName=liuquanmn, createdTime=Thu Aug 13 12:28:44 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428964, encodeId=be41142896478, content=<a href='/topic/show?id=6d4810145692' target=_blank style='color:#2F92EE;'>#马拉松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101456, encryptionId=6d4810145692, topicName=马拉松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=334a4156364, createdName=zxl730, createdTime=Thu Mar 19 08:28:44 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610356, encodeId=28e716103560f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 19 08:28:44 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-03-19 zxl730
  4. [GetPortalCommentsPageByObjectIdResponse(id=2068099, encodeId=07f42068099b6, content=<a href='/topic/show?id=3e9816e266d' target=_blank style='color:#2F92EE;'>#ST2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16726, encryptionId=3e9816e266d, topicName=ST2)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Wed Feb 17 03:28:44 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774447, encodeId=02c81e74447ce, content=<a href='/topic/show?id=a0f3e814af' target=_blank style='color:#2F92EE;'>#Galectin-3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7814, encryptionId=a0f3e814af, topicName=Galectin-3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68c038536731, createdName=liuquanmn, createdTime=Thu Aug 13 12:28:44 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428964, encodeId=be41142896478, content=<a href='/topic/show?id=6d4810145692' target=_blank style='color:#2F92EE;'>#马拉松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101456, encryptionId=6d4810145692, topicName=马拉松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=334a4156364, createdName=zxl730, createdTime=Thu Mar 19 08:28:44 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610356, encodeId=28e716103560f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 19 08:28:44 CST 2020, time=2020-03-19, status=1, ipAttribution=)]